About Nuclear receptor subfamily 2 group E member 1
Nuclear receptor subfamily 2 group E member 1 (NR2E1) is a protein
from Homo sapiens identified by UniProt accession
Q9Y466, 385 residues long.
MolForge cross-references it against 0 known binders and
237 disease associations.
Target properties
| Protein name | Nuclear receptor subfamily 2 group E member 1 |
| UniProt accession | Q9Y466 |
| Gene | NR2E1 |
| Organism | Homo sapiens |
| Length | 385 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (7)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (237)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.38
- alcohol consumption measurement · score 0.28
- Alzheimer disease · score 0.20
- Parkinson disease · score 0.20
- lysosomal storage disease · score 0.20
- multiple sclerosis · score 0.20
- acute myeloid leukemia · score 0.18
- IGF-1 measurement · score 0.09
- neoplasm · score 0.08
- retinitis pigmentosa · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9Y466-F1 | alphafold | PREDICTED | 77.35 | — |
Amino-acid sequence (385 residues)
MSKPAGSTSR ILDIPCKVCG DRSSGKHYGV YACDGCSGFF KRSIRRNRTY VCKSGNQGGC PVDKTHRNQC RACRLKKCLE VNMNKDAVQH ERGPRTSTIR KQVALYFRGH KEENGAAAHF PSAALPAPAF FTAVTQLEPH GLELAAVSTT PERQTLVSLA QPTPKYPHEV NGTPMYLYEV ATESVCESAA RLLFMSIKWA KSVPAFSTLS LQDQLMLLED AWRELFVLGI AQWAIPVDAN TLLAVSGMNG DNTDSQKLNK IISEIQALQE VVARFRQLRL DATEFACLKC IVTFKAVPTH SGSELRSFRN AAAIAALQDE AQLTLNSYIH TRYPTQPCRF GKLLLLLPAL RSISPSTIEE VFFKKTIGNV PITRLLSDMY KSSDI
Explore Nuclear receptor subfamily 2 group E member 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets